South African Special Forces

Recce Pharmaceuticals Announces Anti-Viral Patent Granted in USA for RECCE® Anti-Infectives

Retrieved on: 
Thursday, July 22, 2021

We are thrilled to see that our Anti-viral patent granted in the USA, the largest pharmaceutical market in the world; with yet further market-monopolies reinforcing the unique opportunities among a significant range of both bacterial and viral pathogens.

Key Points: 
  • We are thrilled to see that our Anti-viral patent granted in the USA, the largest pharmaceutical market in the world; with yet further market-monopolies reinforcing the unique opportunities among a significant range of both bacterial and viral pathogens.
  • The U.S. pharma industry has shouldered the responsibility of developing and manufacturing some of the worlds most innovative and best-selling drugs.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Recce Pharmaceuticals Announces Anti-Viral Patent Granted in China for RECCE® Anti-Infectives

Retrieved on: 
Wednesday, July 21, 2021

With this new patent granted in one of the largest pharmaceutical markets in the world, our market-monopolies reinforce the unique opportunities among a significant range of both bacterial and viral pathogens.

Key Points: 
  • With this new patent granted in one of the largest pharmaceutical markets in the world, our market-monopolies reinforce the unique opportunities among a significant range of both bacterial and viral pathogens.
  • This is the third Patent in Family 3 to be granted to the Company following its recent patent grant in Europe and Japan, with applications among other major pharmaceutical markets around the world in their advanced stages of independent patent reviews.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Recce Pharmaceuticals to Present at World Microbe Forum

Retrieved on: 
Monday, June 21, 2021

SYDNEY, Australia, June 21, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, has accepted an invitation to present at the World Microbe Forum following confirmation to publish a recent abstract in the 2021 program.

Key Points: 
  • SYDNEY, Australia, June 21, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, has accepted an invitation to present at the World Microbe Forum following confirmation to publish a recent abstract in the 2021 program.
  • The presentation will be in the format of an iposter (digital poster) with a live virtual Q&A session by Michele Dilizia, Chief Scientific Officer of Recce Pharmaceuticals.
  • The session presents expanded details on recently announced data supporting the Companys lead synthetic anti-infective compound, RECCE 327, and its novel, multi-layered mechanism of action (MoA) at the World Microbe Forum being held virtually on June 20-24, 2021.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

Recce Pharmaceuticals Announces The Pew Charitable Trusts' Addition of Recce’s Lead Compound RECCE® 327 to List of Antibiotic Treatments in Clinical Development

Retrieved on: 
Monday, March 15, 2021

May this bring light to those at risk or suffering from sepsis, an infection for which no specific treatments exist, at this time.

Key Points: 
  • May this bring light to those at risk or suffering from sepsis, an infection for which no specific treatments exist, at this time.
  • The Pew Charitable Trusts stated mission is to serve the public interest by improving public policy, informing the public, and invigorating civic life.
  • The register of non-traditional treatments shows 36 candidates which are in clinical development as of March 2021.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange

Retrieved on: 
Tuesday, March 9, 2021

The dual listing sees trading of the Companys securities on German Trading Exchanges: Frankfurt, Tradegate, Munich, Stuttgart and Gettex.

Key Points: 
  • The dual listing sees trading of the Companys securities on German Trading Exchanges: Frankfurt, Tradegate, Munich, Stuttgart and Gettex.
  • The dual listing was possible without many of the primary listing procedures, seeing a widening of investor reach with minimal cost.
  • Dr. John Prendergast, Chairman of Recce Pharmaceuticals Ltd said, Dual-listing on the Frankfurt Stock Exchange is a wonderful new chapter in our global strategy.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

Recce Pharmaceuticals Provides Business Update

Retrieved on: 
Monday, December 21, 2020

SYDNEY, Australia, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, is pleased to provide an update on its clinical programs.

Key Points: 
  • SYDNEY, Australia, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, is pleased to provide an update on its clinical programs.
  • Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327 and RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE® Anti-Infectives

Retrieved on: 
Monday, November 23, 2020

At now 31 granted patents across three wholly-owned patent families, our market-monopolies reinforce our unique opportunity among a significant-range of both bacterial and viral pathogens.

Key Points: 
  • At now 31 granted patents across three wholly-owned patent families, our market-monopolies reinforce our unique opportunity among a significant-range of both bacterial and viral pathogens.
  • Patent Family 3 applications in other major pharmaceutical markets around the world are in their advanced stages of independent patent reviews.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327 and RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Recce Pharmaceuticals Announces Encouraging Preliminary Results from Antiviral Screening Program at The Doherty Institute Evaluating RECCE® 327 Against SARS-CoV-2

Retrieved on: 
Wednesday, November 11, 2020

SYDNEY, Australia, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of synthetic anti-infectives, today announced encouraging results from the CSIRO/The Peter Doherty Institute for Infection and Immunology (Doherty Institute) Antiviral SARS-CoV-2 Screening Program showing RECCE 327 (R327) had encouraging inhibition of the SARS-CoV-2 virus.

Key Points: 
  • SYDNEY, Australia, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of synthetic anti-infectives, today announced encouraging results from the CSIRO/The Peter Doherty Institute for Infection and Immunology (Doherty Institute) Antiviral SARS-CoV-2 Screening Program showing RECCE 327 (R327) had encouraging inhibition of the SARS-CoV-2 virus.
  • We are interested in seeing the next stage and look forward to continuing research on the effectiveness of R327 with the team at the Doherty Institute.
  • The compound concentration is expressed in parts per million (ppm) as the synthetic polymers in RECCE 327 have a range of molecular weights.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Recce Pharmaceuticals Appoints Synthetic Anti-infectives Expert Michele Dilizia as Chief Scientific Officer

Retrieved on: 
Wednesday, October 14, 2020

SYDNEY, Australia, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing New Classes of Synthetic Anti-Infectives, is pleased to announce the Board of Directors has unanimously appointed Michele Dilizia to the role of Chief Scientific Officer.

Key Points: 
  • SYDNEY, Australia, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing New Classes of Synthetic Anti-Infectives, is pleased to announce the Board of Directors has unanimously appointed Michele Dilizia to the role of Chief Scientific Officer.
  • As co-inventor of Recces Synthetic Anti-Infectives, Micheles significant contributions to the Company reflects her strong scientific acumen and deep expertise in synthetic anti-infectives, said Recce Pharmaceuticals Non-Executive Chairman Dr. John Prendergast.
  • Michele has demonstrated leadership and expertise that has been instrumental to the development of RECCE compounds.
  • Chief Scientific Officer Michele Dilizia said, I am delighted to have been appointed to this role by the Board and it has been my privilege to contribute to the development of a unique technology like RECCE Anti-Infectives.

Recce Pharmaceuticals Completes Capital Raising of $27.95 Million

Retrieved on: 
Wednesday, September 23, 2020

We greatly appreciate the support shown by both our existing investors and new institutional investors, said Recce Pharmaceuticals Chief Executive Officer James Graham.

Key Points: 
  • We greatly appreciate the support shown by both our existing investors and new institutional investors, said Recce Pharmaceuticals Chief Executive Officer James Graham.
  • Their financial support comes at a transformative time for Recce as we prepare to advance human clinical trials.
  • Proceeds will be used to advance Recces synthetic anti-infective pipeline comprised of RECCE 327, RECCE 435 and RECCE 529 to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.